GLP-1 medications are extraordinarily effective — but they are not infallible, and patient behavior during treatment significantly affects outcomes. Clinical practice and post-marketing experience have identified a consistent set of mistakes that reduce effectiveness, increase side effects, or cause premature discontinuation. Here are the seven most common, with evidence-based corrections for each.
Why this matters
The STEP 1 trial demonstrated 14.9% average weight loss — but that is an average across a highly controlled trial population with intensive lifestyle counseling. Real-world outcomes vary significantly. Patients who make these mistakes often plateau at 5–8% weight loss when 12–15% is achievable with the same medication and the corrections below.
Mistake 1: Not Eating Enough Protein
GLP-1 medications suppress appetite broadly — but they do not distinguish between protein, carbohydrates, and fat. Many patients on GLP-1 therapy reduce caloric intake dramatically without maintaining adequate protein, resulting in significant lean mass (muscle) loss rather than primarily fat loss.
In the STEP 1 DXA substudy, approximately 39% of total weight lost came from lean body mass.1 This is clinically significant: muscle loss reduces basal metabolic rate, increases frailty risk in older adults, and makes weight regain more likely when treatment ends.
The fix: Target at minimum 1.2–1.6g of protein per kilogram of body weight per day, distributed across meals. Prioritize protein at every meal, especially as meal sizes shrink. Protein shakes can supplement intake if solid protein sources are difficult to tolerate during the side effect phase.
Mistake 2: Skipping Resistance Exercise
Aerobic exercise is often emphasized for weight loss, but resistance training (strength training) is specifically important during GLP-1 therapy to preserve lean mass. A systematic review found that progressive resistance exercise during pharmacotherapy-assisted weight loss significantly reduced the proportion of weight lost from muscle versus fat.
The fix: 2–3 resistance training sessions per week targeting major muscle groups, combined with 150 minutes of moderate aerobic activity weekly (the minimum recommended by AHA/ACC cardiovascular guidelines).2 If you are new to strength training, bodyweight exercises (squats, push-ups, rows) are an appropriate starting point.
Find a GLP-1 option matched to your state and budget in 60 seconds.
Get My Match →Mistake 3: Eating Ultra-Processed Foods
GLP-1 medications suppress appetite for standard meals more effectively than for highly palatable ultra-processed foods. The food reward circuitry suppression is real but not absolute — the palatability engineering in chips, cookies, and fast food is specifically designed to override normal satiety signals. Patients who eat primarily ultra-processed foods may find they can continue consuming significant calories despite apparent appetite suppression.
The fix: Shift toward whole food sources — lean proteins, vegetables, legumes, fruits, and whole grains. These foods engage satiety pathways more effectively alongside GLP-1 receptor agonist therapy. This is not about perfection — it is about shifting the ratio in your eating pattern.
Mistake 4: Drinking Alcohol Regularly
Alcohol is calorie-dense (7 kcal/gram), impairs satiety signaling, reduces decision-making quality around food choices, and can intensify GLP-1-related GI side effects. Additionally, there is emerging clinical concern about a shift in addictive behavior patterns in some patients on GLP-1 therapy — the same dopaminergic reward suppression that reduces food drive may alter the reward response to alcohol.
The fix: Significantly reduce alcohol intake during GLP-1 therapy. For most patients, eliminating it during the dose escalation phase reduces nausea substantially. If alcohol consumption continues, track it as part of your caloric accounting — it is easy to undercount.
Mistake 5: Stopping the Medication During Side Effects
Nausea during dose escalation is the most common reason for premature discontinuation of GLP-1 therapy — and it is often unnecessary. In the STEP 1 trial, 44.2% of participants reported nausea, but only 4.5% discontinued due to GI adverse events.3 The vast majority pushed through the escalation phase to significant clinical benefit.
The fix: Before stopping the medication for nausea, contact your prescriber. Options include: extending time at the current dose before escalating further, temporarily reducing to a lower dose, adjusting injection timing (evening injections may reduce daytime nausea), and anti-nausea dietary modifications (ginger tea, smaller meals, avoiding lying down after eating). Stopping prematurely costs the clinical investment you have already made.
Mistake 6: No Clinical Monitoring After the First Prescription
Some telehealth programs issue a prescription and then offer minimal follow-up. Patients who go months without clinical contact miss opportunities to identify non-response early, adjust dosing for tolerability, monitor for side effects requiring intervention, and address behavioral factors affecting outcomes.
The fix: Choose a program with structured follow-up — at minimum a quarterly clinical check-in. Track weight weekly. Monitor for side effects. Communicate with your care team when something feels wrong. GLP-1 therapy is a medical treatment, not a supplement — it warrants medical oversight throughout.
Mistake 7: Stopping When You Reach Your Goal
The most costly mistake in GLP-1 therapy is discontinuing when target weight is reached, assuming the work is done. The STEP 4 trial demonstrated clearly: patients who discontinued semaglutide after 20 weeks regained approximately two-thirds of lost weight over the following 48 weeks — returning to near-baseline weight within one year.4
The fix: Plan for long-term therapy before starting. Discuss a maintenance plan with your physician when you approach your goal weight. Some patients successfully taper to a lower maintenance dose; most benefit from continued therapy. Stopping should be a deliberate clinical decision, not a default assumption that the treatment is complete.
To find a program with structured monitoring and ongoing clinical support, use our matching tool — filtered to your state and budget.